Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Executive Summary

How will the confirmatory trial necessary to convert accelerated approval to full approval affect sales given the small size of the target population?


Related Content

PTC Tumbles On Ataluren Failure In Cystic Fibrosis
Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations
Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs
FDA Refuses To File Translarna NDA; PTC Plummets
Duchenne Muscular Dystrophy: Second Product Isn't The Charm
Lessons From Avastin: Accelerated Approval Needs “Easy On, Easy Off” Mechanism, Pazdur Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts